{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T12:11:40Z","timestamp":1763727100410,"version":"3.37.3"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,12,16]],"date-time":"2016-12-16T00:00:00Z","timestamp":1481846400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1038\/nrneurol.2016.190","type":"journal-article","created":{"date-parts":[[2016,12,17]],"date-time":"2016-12-17T06:44:38Z","timestamp":1481957078000},"page":"7-9","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Gene-editing therapy for neurological disease"],"prefix":"10.1038","volume":"13","author":[{"given":"Moira A.","family":"McMahon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Don W.","family":"Cleveland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,12,16]]},"reference":[{"key":"BFnrneurol2016190_CR1","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","volume":"337","author":"M Jinek","year":"2012","unstructured":"Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816\u2013821 (2012).","journal-title":"Science"},{"key":"BFnrneurol2016190_CR2","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1126\/science.1231143","volume":"339","author":"L Cong","year":"2013","unstructured":"Cong, L. et al. Multiplex genome engineering using CRISPR\/Cas systems. Science 339, 819\u2013823 (2013).","journal-title":"Science"},{"key":"BFnrneurol2016190_CR3","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1146\/annurev-pathol-011811-132457","volume":"7","author":"MR Santoro","year":"2012","unstructured":"Santoro, M. R., Bray, S. M. & Warren, S. T. Molecular mechanisms of fragile X syndrome: a twenty-year perspective. Annu. Rev. Pathol. 7, 219\u2013245 (2012).","journal-title":"Annu. Rev. Pathol."},{"key":"BFnrneurol2016190_CR4","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.celrep.2015.08.084","volume":"13","author":"C-Y Park","year":"2015","unstructured":"Park, C.-Y. et al. Reversion of FMR1 methylation and silencing by editing the triplet repeats in fragile X iPSC-derived neurons. Cell Rep. 13, 234\u2013241 (2015).","journal-title":"Cell Rep."},{"key":"BFnrneurol2016190_CR5","doi-asserted-by":"publisher","first-page":"e0165499","DOI":"10.1371\/journal.pone.0165499","volume":"11","author":"N Xie","year":"2016","unstructured":"Xie, N. et al. Reactivation of FMR1 by CRISPR\/Cas9-mediated deletion of the expanded CGG-repeat of the fragile X chromosome. PLoS ONE 11, e0165499 (2016).","journal-title":"PLoS ONE"},{"doi-asserted-by":"publisher","unstructured":"Shin, J. W. et al. Permanent inactivation of Huntington's disease mutation by personalized allele-specific CRISPR\/Cas9. Hum. Mol. Genet. http:\/\/dx.doi.org\/10.1093\/hmg\/ddw286 (2016).","key":"BFnrneurol2016190_CR6","DOI":"10.1093\/hmg\/ddw286"},{"key":"BFnrneurol2016190_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nm.3793","volume":"21","author":"DB Cox","year":"2015","unstructured":"Cox, D. B., Platt, R. J. & Zhang, F. Therapeutic genome editing: prospects and challenges. Nat. Med. 21, 121\u2013131 (2015).","journal-title":"Nat. Med."},{"key":"BFnrneurol2016190_CR8","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1038\/mt.2013.211","volume":"21","author":"KD Foust","year":"2013","unstructured":"Foust, K. D. et al. Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS. Mol. Ther. 21, 2148\u20132159 (2013).","journal-title":"Mol. Ther."},{"key":"BFnrneurol2016190_CR9","doi-asserted-by":"crossref","first-page":"E7110","DOI":"10.1073\/pnas.1520883112","volume":"112","author":"M Rahdar","year":"2015","unstructured":"Rahdar, M. et al. Synthetic CRISPR RNA\u2013Cas9-guided genome editing in human cells. Proc. Natl Acad. Sci. USA 112, E7110\u2013E7117 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2016190_CR10","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1172\/JCI25424","volume":"116","author":"RA Smith","year":"2006","unstructured":"Smith, R. A. et al. Antisense oligonucleotide therapy for neurodegenerative disease. J. Clin. Invest. 116, 2290\u20132296 (2006).","journal-title":"J. Clin. Invest."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2016.190.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2016.190","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2016.190.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:19:19Z","timestamp":1684469959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneurol.2016.190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,16]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["BFnrneurol2016190"],"URL":"https:\/\/doi.org\/10.1038\/nrneurol.2016.190","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"type":"print","value":"1759-4758"},{"type":"electronic","value":"1759-4766"}],"subject":[],"published":{"date-parts":[[2016,12,16]]},"assertion":[{"value":"16 December 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.W.C. has been a consultant for Ionis Pharmaceuticals since 2003. M.A.M. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}